167 related articles for article (PubMed ID: 30696657)
1. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Bastea LI; Liou GY; Pandey V; Fleming AK; von Roemeling CA; Doeppler H; Li Z; Qiu Y; Edenfield B; Copland JA; Tun HW; Storz P
Cancer Res; 2019 Apr; 79(7):1535-1548. PubMed ID: 30696657
[TBL] [Abstract][Full Text] [Related]
2. The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis.
Liou GY; Bastea L; Fleming A; Döppler H; Edenfield BH; Dawson DW; Zhang L; Bardeesy N; Storz P
Cell Rep; 2017 May; 19(7):1322-1333. PubMed ID: 28514653
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
4. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice.
Minegishi Y; Hiroshima Y; Yazawa K; Sato S; Yabushita Y; Homma Y; Matsuyama R; Kato I; Goshima Y; Endo I
Anticancer Res; 2022 Feb; 42(2):791-799. PubMed ID: 35093877
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Fujiwara Y; Sun Y; Torphy RJ; He J; Yanaga K; Edil BH; Schulick RD; Zhu Y
Cancer Res; 2018 Dec; 78(23):6655-6665. PubMed ID: 30315115
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Li Z; Qiu Y; Personett D; Huang P; Edenfield B; Katz J; Babusis D; Tang Y; Shirely MA; Moghaddam MF; Copland JA; Tun HW
PLoS One; 2013; 8(8):e71754. PubMed ID: 23940785
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
8. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
9. Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages.
Wang B; Zheng X; Liu J; Zhang Z; Qiu C; Yang L; Zhang L; Zhang Q; Gao H; Wang X
J Pharmacol Sci; 2018 Jul; 137(3):290-298. PubMed ID: 30098910
[TBL] [Abstract][Full Text] [Related]
10. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.
Liou GY; Döppler H; Necela B; Edenfield B; Zhang L; Dawson DW; Storz P
Cancer Discov; 2015 Jan; 5(1):52-63. PubMed ID: 25361845
[TBL] [Abstract][Full Text] [Related]
11. Roles of differently polarized macrophages in the initiation and progressionof pancreatic cancer.
Storz P
Front Immunol; 2023; 14():1237711. PubMed ID: 37638028
[TBL] [Abstract][Full Text] [Related]
12. Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas.
Maier HJ; Wagner M; Schips TG; Salem HH; Baumann B; Wirth T
Oncogene; 2013 May; 32(21):2690-5. PubMed ID: 22751123
[TBL] [Abstract][Full Text] [Related]
13. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras
Janakiram NB; Mohammed A; Bryant T; Ritchie R; Stratton N; Jackson L; Lightfoot S; Benbrook DM; Asch AS; Lang ML; Rao CV
Immunology; 2017 Sep; 152(1):36-51. PubMed ID: 28419443
[TBL] [Abstract][Full Text] [Related]
14. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
15. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.
Biankin AV; Kench JG; Morey AL; Lee CS; Biankin SA; Head DR; Hugh TB; Henshall SM; Sutherland RL
Cancer Res; 2001 Dec; 61(24):8830-7. PubMed ID: 11751405
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
Griesmann H; Drexel C; Milosevic N; Sipos B; Rosendahl J; Gress TM; Michl P
Gut; 2017 Jul; 66(7):1278-1285. PubMed ID: 27013602
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
